The simulated binding of (±)-2,3-dihydro-5,6-dimethoxy-2-[[1- (phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one hydrochloride (E2020) and related inhibitors to free and acylated acetylcholinesterases and corresponding structure-activity analyses

Journal of Medicinal Chemistry

Volumn 39, Issue 22, 1996, Pages 4460-4470

  Inoue, Atsushi ^a   Kawai, Takatoshi ^a   Wakita, Misako ^a   Iimura, Youichi ^a   Sugimoto, Hachiro ^a   Kawakami, Yoshiyuki ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; DONEPEZIL; ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ACYLATION; ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; CHOLINERGIC TRANSMISSION; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; DRUG RECEPTOR BINDING; ENZYME INHIBITION; LIGAND BINDING; NONHUMAN; STRUCTURE ACTIVITY RELATION; BINDING SITE; CHEMICAL STRUCTURE; ISOMERISM; KINETICS; METABOLISM; PROTEIN CONFORMATION;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ACYLATION; BINDING SITES; CHOLINESTERASE INHIBITORS; INDANS; ISOMERISM; KINETICS; MODELS, MOLECULAR; PIPERIDINES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029662318     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950596e     Document Type: Article

References (35)

1. Homma, A.; Hasegawa, K.; Nishimura, T.; Kameyama, M.; Hariguchi, S.; Imai, Y. Clinical Efficacy Of E-2020 in Treatment of Patients with Probable Alzheimer's Disease: Part 2. Double Blind Placebo Controlled Study. In The Proceedings of 6th Congress of the International Psychogerica Association, 1993.
2. Yamanishi, Y.; Ogura, H.; Kosasa, K.; Araki, S.; Sawa, Y.; Yamatsu, K. Inhibitory Action of E2020, A Novel Acetylcholinesterase Inhibitor, on Cholinesterase: Comparison with Other Inhibitors. In Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, Volume 2; Plenum Press: New York, 1990; p 409.
3. Bartus, R. T.; Dean, R. L., III; Beer, B.; Lippa, A. S. The Cholinergic Hypothesis of Geriatric Memory Dysfunction. Science 1982, 217, 408.
4. Sims, N. R.; Bowen, D. M.; Allen, S. J.; Smith, C. C. T.; Neary, D.; Thomas, D. J.; Davison, A. N. Presynaptic Cholinergic Dysfunction in Patients. J. Neurochem. 1983, 40, 503.
5. Gottfries, C. G. Pharmacological Treatment Strategies in Alzheimer Type Dementia. Psychopharmacology 1985, 86, 245.
6. Perry, E. K. The Cholinergic Hypothesis-Ten Years on. Br. Med. Bull. 1986, 42, 63.
7. Summers, W. K.; Koehler, A. L.; Marsh, A. M.; Tachiki, K.; Kling, A. Long-Term Hepatotoxicity of Tacrine. Lancet 1989, 33, 729.
8. Sugimoto, H.; Tsuchiya, Y.; Sugumi, H.; Higurashi, K.; Karibe, N.; Iimura, Y.; Sasaki, A.; Kawakami, Y.; Nakamura, T.; Araki, S.; Yamanishi, Y. Novel Piperidine Derivatives. Synthesis and Anti-Acetylcholinesterase Activity Of 1-Benzyl-4-[2-(N-benzoylamino)ethyl]piperidine Derivatives. J. Med. Chem. 1990, 33, 1880.
9. Kawakami, Y.; Inoue, A.; Kawai, T.; Wakita, M.; Sugimoto, H.; Hopfinger, A. J. The Rationale for E2020 as a Potent Acetylcholinesterase Inhibitor. BioOrg. Med. Chem., in press.
10. Cardozo, M. G.; Imura, Y.; Sugiomoto, H.; Yamanishi, Y.; Hopfinger, A. J. QSAR Analyses of the Substituted Indanone and Benzylpiperidine Rings of a Series of Indanone-Benzylpiperidine Inhibitors of Acetylcholinesterase. J. Med. Chem. 1992, 35, 584.
11. Cardozo, M. G.; Kawai, T.; Iimura, Y.; Sugimoto, H.; Yamanishi, Y.; Hopfinger, A. J. Conformational Analyses and Molecular-Shape Comparisons of a Series of Indanone-Benzylpiperidine Inhibitors of Acetylcholinesterase. J. Med. Chem. 1992, 35, 590.
12. Kawakami, Y.; Kawai, T.; Inoue, A.; Iimura, Y.; Sugimoto, H.; Yoshida, Y.; Sato, T. E2020: The Rational Design of a Potent Acetylcholinesterase Inhibitor. In The Proceedings of 14th Symposium on Medicinal Chemistry (Japan), 1993, p 19.
13. Ishihara, Y.; Hirai, K.; Miyamoto, M.; Goto, G. Central Cholinergic Agents. 6. Synthesis and Evaluation of 3-[1-(Phenyl-methyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- 1-propanones and Their Analogs as Central Selective Acetylcholinesterase. J. Med. Chem. 1993, 37, 2292.
14. Villalobos, A.; Blake, J. F.; Biggers, C. K.; Butler, T. W.; Chapin, D. S.; Chen, Y. L.; Ives, J. L.; Jones, S. B.; Liston, D. R., Nage, A. A.; Nason, D. M.; Nielsen, J. A.; Shalaby, I. A.; White, W. F. Novel Benzisoxazole Derivatives as Potent and Selective Inhibitors of Acetylcholinesterase. J. Med. Chem. 1994, 37, 2721.
15. Tong, W.; Collantes, E. R.; Yu, C.; Welsh, W. J. A Comparative Molecular Field Analysis Study of N-Benzylpiperidines as Acetylcholinesterase Inhibitors. J. Med. Chem. 1996, 39, 380.
16. Sussman, J. L.; Harel, M.; Frolow, F.; Offner, C.; Goldman, A.; Toker, L.; Siman, I. Atomic Structure of Acetylcholinesterase from Torpedo californica: A Prototypic Acetylcholine-Binding Protein. Science 1991, 253, 872.
17. Yamamoto, Y.; Ishihara, Y.; Kuntz, I. D. Docking Analysis of a Series of Benzylamino Acetylcholinesterase Inhibitors with a Phthalimide, Benzoyl, or Indanone Moiety. J. Med. Chem. 1994, 37, 3141.
18. Yuan-Ping, P.; Alan, P. K. Prediction of the Binding Site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by Docking Studies with the SYSDOC Program. J. Comput. Aided Mol. Des. 1994, 8, 683.
19. Nochi, S.; Asakawa, N.; Sato, T. Kinetic Study on the Inhibition of Acetylcholinesterase by 1-Benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine Hydrochloride (E2020). Biol. Pharm. Bull. 1995, 18, 1145.
20. (a) Tomioka, N.; Itai, A. GREEN: A Program Package for Docking Studies in Rational Drug Design. J. Comput.-Aided Mol. Des. 1994, 8, 347.
21. (b) GREEN V4.0, PDBFIL. Distributed by the Institute of Medicinal Melecular Design, 5-24-5, Kongo, Bunkyo-ku, Tokyo 113, Japan (1995).
22. Weiner, S. J.; Kollman, P. A. An All Atom Force Field for Simulations of Proteins and Nucleic Acids. J. Comput. Chem. 1986, 7, 230.
23. Dewer, M. J. S.; Thiel, W. Ground States of Molecules. 38. The MNDO Method. Approximations and Parameters. J. Am. Chem. Soc. 1977, 99, 4899.
24. Insight II/DelPhi, Release 95.0. Distributed by the Molecular Simulations Inc., 9685 Scranton Rd., San Diego, CA 92121-3752, 1995.
25. CAVHET is the original program developed by A. Inoue. Eisai Tsukuba Research Laboratories, 5-1-3, Tokodai, Tsukuba, Ibaraki 300-26, Japan, 1995.
26. Neider, J. A.; Mead, R. A simplex method for function minimization. Comput. J. 1965, 7, 308.
27. Hopfinger, A. J. Conformational Properties of Macromolecules; Academic Press: New York, 1973.
28. Harel, M.; Shalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P. H.; Silman, I.; Sussman, J. L. Quaternary Ligand Binding to Aromatic Residues in the Active-Site Gorge of Acetylcholinesterase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9031.
29. Ripoll, D. R.; Faermam, C. H.; Axelsen, P. H.; Silman, I.; Sussman, J. L. An Electrostatic Mechanism for Substrate Guidance Down the Aromatic Gorge of Acetylcholinesterase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 5128.
30. Raymond, C. T.; Thanh, N. T.; McCammon, J. A. Acetylcholinesterase: Electrostatic Steering Increases the Rate of Ligand Binding. Biochemistry 1993, 32, 401.
31. Krupka, R. M.; Laidler, K. L. Molecular Mechanisms for Hydrolytic Enzyme Action. I. Apparent Non-competitive Inhibition, with Special Reference to Acetylcholinesterase. J. Am. Chem. Soc. 1961, 83, 1445.
32. Krupka, R. M.; Laidler, K. J. Molecular Mechanisms for Hydrolytic Enzyme Action. III. A General Mechanism for the Inhibition of Acetylcholinesterase. J. Am. Chem. Soc. 1961, 83, 1454.
33. Krupka, R. M. Acetylcholinesterase: Structural Requirements for Blocking Deacetylation. Biochemistry 1965, 4, 429.
34. Gilson, M. K.; Strastsma, T.; McCammon, J. A. Open "Back Door" in a Molecular Dynamics Simulation of Acetylcholinesterase. Science 1994, 263, 1276.
35. Hopfinger, A. J.; Tokarski, J. Private communication.